Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 3/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.63 |
| ▸ | THRA | P10827 | 1/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.60 |
| ▸ | PRSS1 | P07477 | 7/20 | 0.59 |
| ▸ | PARP1 | P09874 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14421817 | 0.98 | SMPD1 (0.70) | SMPD1KMT2APLA2G4BTHRATHRB | |
| SCHEMBL201242 | 0.98 | SMPD1 (0.70) | SMPD1KMT2APLA2G4BTHRATHRB | |
| SCHEMBL12951117 | 0.98 | SMPD1 (0.70) | SMPD1KMT2APLA2G4BTHRATHRB | |
| SCHEMBL204298 | 0.98 | SMPD1 (0.70) | SMPD1KMT2APLA2G4BTHRATHRB | |
| SCHEMBL202777 | 0.98 | SMPD1 (0.70) | SMPD1KMT2APLA2G4BTHRATHRB | |
| SCHEMBL202638 | 0.98 | SMPD1 (0.70) | SMPD1KMT2APLA2G4BTHRATHRB | |
| SCHEMBL201450 | 0.95 | KMT2A (0.62) | SMPD1KMT2APLA2G4BTHRATHRB | |
| SCHEMBL202142 | 0.93 | SMPD1 (0.60) | SMPD1KMT2APLA2G4BTHRATHRB | |
| SCHEMBL12434144 | 0.92 | SMPD1 (0.59) | SMPD1KMT2APLA2G4BTHRATHRB | |
| SCHEMBL201978 | 0.92 | SMPD1 (0.62) | SMPD1KMT2APLA2G4BTHRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102008459-B | Antibacterial agents | BIOTA SCIENT MAN | 2013-05-29 | — | — | CN | claimed |
| EP-0749415-B1 | BENZAMIDE ANALOGS, USEFUL AS PARP (ADP-RIBOSYLTRANSFERASE, ADPRT) DNA REPAIR ENZYME INHIBITORS | UNIV NEWCASTLE VENTURES LTD (GB) | 1999-09-08 | — | — | EP | claimed |
| JP-H09510704-A | — | — | 1997-10-28 | — | — | JP | claimed |
| EP-0749415-A1 | BENZAMIDE ANALOGS, USEFUL AS PARP (ADP-RIBOSYLTRANSFERASE, ADPRT) DNA REPAIR ENZYME INHIBITORS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1996-12-27 | — | — | EP | claimed |
| WO-1995024379-A1 | BENZAMIDE ANALOGS, USEFUL AS PARP (ADP-RIBOSYLTRANSFERASE, ADPRT) DNA REPAIR ENZYME INHIBITORS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1995-09-14 | — | — | WO | claimed |
| US-20250179008-A1 | ANTIBACTERIAL AGENTS | TAXIS PHARMACEUTICALS, INC. (US) | 2025-06-05 | — | — | US | disclosed |
| CN-103608350-B | Triazolopyridine compounds | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-11-25 | — | — | CN | disclosed |
| US-20150191420-A1 | ANTIBACTERIAL AGENTS | TAXIS PHARMACEUTICALS, INC. | 2015-07-09 | — | — | US | disclosed |
| US-20150191420-A1 | ANTIBACTERIAL AGENTS | TAXIS PHARMACEUTICALS, INC. | 2015-07-09 | — | — | US | disclosed |
| US-20150191420-A1 | ANTIBACTERIAL AGENTS | TAXIS PHARMACEUTICALS, INC. | 2015-07-09 | — | — | US | disclosed |
| US-8865736-B2 | Antibacterial agents | Biota Scientific Pty Ltd (AU) | 2014-10-21 | — | — | US | disclosed |
| US-8865736-B2 | Antibacterial agents | Biota Scientific Pty Ltd (AU) | 2014-10-21 | — | — | US | disclosed |
| CN-101404989-A | Antibacterial agent | PROLYSIS LTD (GB) | 2009-04-08 | — | — | CN | disclosed |
| WO-2007107758-A1 | ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2007-09-27 | — | — | WO | disclosed |
| US-6316455-B1 | Method of improving the effectiveness of a cytotoxic drug or radiotherapy using a quinazolinone compound | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 2001-11-13 | — | — | US | disclosed |
| US-6015827-A | Benzoxazole-4-carboxamides and their use in inhibiting poly (adp-ribose) polymerase activity and improving cytotoxic effectiveness of cytotoxic drugs or radiotherapy | NEWCASTLE UNIVERSITY VENTURES LIMITED | 2000-01-18 | — | — | US | disclosed |
| EP-0749415-B1 | BENZAMIDE ANALOGS, USEFUL AS PARP (ADP-RIBOSYLTRANSFERASE, ADPRT) DNA REPAIR ENZYME INHIBITORS | UNIV NEWCASTLE VENTURES LTD (GB) | 1999-09-08 | — | — | EP | disclosed |
| US-5756510-A | POTENTIATE EFFECTS OF CYTOTOXIC DRUGS OR RADIOTHERAPY | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1998-05-26 | — | — | US | disclosed |
| EP-0749415-A1 | BENZAMIDE ANALOGS, USEFUL AS PARP (ADP-RIBOSYLTRANSFERASE, ADPRT) DNA REPAIR ENZYME INHIBITORS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1996-12-27 | — | — | EP | disclosed |
| WO-1995024379-A1 | BENZAMIDE ANALOGS, USEFUL AS PARP (ADP-RIBOSYLTRANSFERASE, ADPRT) DNA REPAIR ENZYME INHIBITORS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1995-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150191420-A1 | ANTIBACTERIAL AGENTS | ALK, ARG1, ROS1 | SMPD1 1525/4885KMT2A 415/4885PLA2G4B 4725/4885 |
| US-20250179008-A1 | ANTIBACTERIAL AGENTS | ALK, ROS1, NOX1 | SMPD1 1055/4885KMT2A 1011/4885PLA2G4B 4704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.